Compare FLYX & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FLYX | PYPD |
|---|---|---|
| Founded | 2015 | 2008 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Blank Checks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.2M | 86.6M |
| IPO Year | N/A | 2014 |
| Metric | FLYX | PYPD |
|---|---|---|
| Price | $2.49 | $4.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $12.25 |
| AVG Volume (30 Days) | ★ 826.0K | 44.7K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.47 | N/A |
| Revenue Next Year | $15.15 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.88 | $2.44 |
| 52 Week High | $8.88 | $5.12 |
| Indicator | FLYX | PYPD |
|---|---|---|
| Relative Strength Index (RSI) | 55.02 | 50.13 |
| Support Level | $2.42 | $4.26 |
| Resistance Level | $2.59 | $5.05 |
| Average True Range (ATR) | 0.24 | 0.19 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 37.15 | 38.46 |
flyExclusive Inc is an owner and operator of curated private aviation experiences dedicated to surpassing passenger expectations for quality, convenience, and safety. Its mission is to be the world's majority vertically integrated private aviation company through capital-efficient program growth, an industry pricing model, optimal dispatch availability, in-house training, and a controlled premium customer experience on modernized aircraft. The company has over 100 aircraft in its owned and leased fleet, which includes light, midsize, super-midsize, and large jets. As one of the nation's Citation operators, it has curated a versatile fleet of Citation CJ3/CJ3 plus, Citation Excel/XLS/XLS plus, Citation Encore/Encore plus, Citation Sovereign, and Citation X aircraft.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.